Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025.

Original from: Roche - Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. - Sales in the fourth quarter increased b..

Original from: Danaher Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations a..

BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders. Immediately following the spin-off, the spun-off entity will be combined with Waters Corporation (NYSE: WAT) ("Waters") in a Reverse Morris Trust transaction. The combination is expected to be completed on February 9, 2026, subject to the satisfaction of customary closing conditions.

The instruments employed by hospitals participating in the basic study were mainly from various manufacturers such as Sysmex, Stago, Werfen, Sekisui, Beckman, Mindray, Succeeder, BSBE, and Rayto, involving 96 instrume..

Recently, an outbreak of Nipah virus occurred in West Bengal, India, with 5 confirmed cases reported, including several healthcare workers. Nearly 100 people have been placed under home quarantine, and one patient is ..

The Fujian Agriculture and Forestry University in East China has unveiled the country's first humanoid diagnostic and treatment robot that deeply integrates non-invasive brain computer interface (BCI) technology. The robot is expected to help address long-standing challenges in early intervention of autism and other neurodevelopmental disorders, bringing good hope to the rehabilitation of more than 13 million autism patients in China, Global Times learned from the robot developers on Sunday.

Diasorin (FTSE MIB: DIA) announced today that, following the recent 510(k) clearance and CLIA-waiver from the U.S. Food and Drug Administration (FDA) for its first assay—the FLU A/B, RSV & COVID-19 Panel for use on the LIAISON NES® platform— the Company has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, for the LIAISON NES® molecular point-of-care (POC) platform in the U.S. hospital market.

Qure.ai, a global digital health company focused on AI-led medical diagnostics, has received a multi-million-dollar grant from the Gates Foundation to support the development of AI-enabled point-of-care ultrasound and create an open-source multi-modal health database aimed at improving lung disease detection in underserved regions.

Merck (MRK.N), opens new tab is no longer in discussions to buy cancer drug developer Revolution Medicines (RVMD.O), opens new tab, the Wall Street Journal reported on Sunday.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.

HORIBA, a global leader in analytical and measurement technology, has obtained CE IVDR certification for its new Yumizen H500 CRP benchtop hematology analyzer which delivers a simultaneous 5-part extended differential (DIFF) and rapid C-Reactive Protein (CRP) whole blood measurement. Based on its award winning Yumizen H500 compact analyzer, the new instrument is designed for small laboratories and ideal for use in a variety of hospital testing settings for rapid and highly accurate detection of infection and inflammation.

BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing of an additional $8 million. The financing marks a key inflection point as the company transitions from building a differentiated global diagnostics and data infrastructure to scaling an AI-native platform – while continuing to expand its comprehensive molecular testing reach across Latin America – designed to accelerate drug and diagnostic development, improve clinical trial execution, and enable precision oncology at global scale.

Truvian Health (“Truvian”), a diagnostics company redefining routine blood testing, today announced U.S. Food and Drug Administration (FDA) clearance for the Complete Blood Count (CBC) on its TruVerus™ multi‑modal blood testing system (K251249).

In November 2025, China's National Health Commission and four other authorities have called for the broader application of artificial intelligence (AI) in the country's health sector over the coming years. ..